drugset / Trial / NCT07163910
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
Phase 2
Recruiting
93 enrolled
baotai Liang
Subei People's Hospital of Jiangsu Province · collabThe Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China · collabThe First People Hospital of Nantong City · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The project aims to verify the therapeutic effect of neoadjuvant homoharringtonine combined with androgen deprivation therapy in patients with localized high-risk/very high-risk, regional lymph node-metastatic, or metastatic prostate cancer before radical prostatectomy through clinical trials, thereby identifying an effective treatment for patients with advanced prostate cancer.
Timeline
- Start
- 2025-04-20
- Primary completion
- 2027-09-20
- Completion
- 2027-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Homoharringtonine | Small molecule | 1 mg | Intravenous |